The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of immune checkpoint inhibitor (ICI) regimens are unknown. OBJECTIVE: To compare the incidence and risk of endocrine AEs following treatment with US Food and Drug Administration-approved ICI regimens. DATA SOURCES: A PubMed search through July 18, 2016, using the following keywords was performed: "ipilimumab," "MDX-010," "nivolumab," "BMS-963558," "pembrolizumab," "MK-3475," "atezolizumab," "MPDL3280A," and "phase." STUDY SELECTION: Thirty-eight randomized clinical trials evaluating the usage of these ICIs for treatment of advanced solid tumors were identified, resulting in a total of 7551 patients who were eligible for a meta-analysis. Regimens were categorized by class into monotherapy with a PD-1 (programmed cell death protein 1) inhibitor, a CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) inhibitor, or a PD-L1 (programmed cell death 1 ligand 1) inhibitor, and combination therapy with PD-1 plus CTLA-4 inhibitors. DATA EXTRACTION AND SYNTHESIS: The data were extracted by 1 primary reviewer (R.B.-S.) and then independently reviewed by 2 secondary reviewers (W.T.B. and A.C.G.-C.) following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Inferences on the incidence of AEs were made using log-odds random effects models. MAIN OUTCOMES AND MEASURES: Incidence of all-grade hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, and insulin-deficient diabetes. RESULTS: Overall, 38 randomized clinical trials comprising 7551 patients were included in this systematic review and meta-analysis. The incidence of both hypothyroidism and hyperthyroidism was highest in patients receiving combination therapy. Patients on the combination regimen were significantly more likely to experience hypothyroidism (odds ratio [OR], 3.81; 95% CI, 2.10-6.91, P < .001) and hyperthyroidism (OR, 4.27; 95% CI, 2.05-8.90; P = .001) than patients on ipilimumab. Compared with patients on ipilimumab, those on PD-1 inhibitors had a higher risk of developing hypothyroidism (OR, 1.89; 95% CI, 1.17-3.05; P = .03). The risk of hyperthyroidism, but not hypothyroidism, was significantly greater with PD-1 than with PD-L1 inhibitors (OR, 5.36; 95% CI, 2.04-14.08; P = .002). While patients who received PD-1 inhibitors were significantly less likely to experience hypophysitis than those receiving ipilimumab (OR, 0.29; 95% CI, 0.18-0.49; P < .001), those who received combination therapy were significantly more likely to develop it (OR, 2.2; 95% CI, 1.39-3.60; P = .001). For primary adrenal insufficiency and insulin-deficient diabetes no statistical inferences were made due to the smaller number of events. CONCLUSIONS AND RELEVANCE: Our study provides more precise data on the incidence of endocrine dysfunctions among patients receiving ICI regimens. Patients on combination therapy are at increased risk of thyroid dysfunction and hypophysitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The occurrence of AI in ICI users has been reported in about 1% of cases and more frequently in individuals receiving combination regimens like anti-CTLA4 plus anti-PD1/PD-L1 agents (4%-8%) (25, 28, 29).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While hypothyroidism and thyrotoxicosis have been mainly associated with anti-PD1/PDL1 agents (especially in a combination regimen with anti-CTLA4, co-occurring with hepatobiliary and respiratory irAEs), hypophysitis, AI, and hypopituitarism were more frequently reported with anti-CTLA4 drugs (ipilimumab) (25, 26).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ICI-diabetes is an insulin-deficient phenotype that presents as acute severe hyperglycemia or DKA and appears to occur more abruptly than type 1 diabetes (216-218).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [217]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint inhibitors (ICIs) (agents that block programmed cell death protein 1 [PD-1] and programmed cell death protein ligand 1 [PD-L1]) suppress physiologic blocks on immune responses, which can result in autoimmune toxicities, including autoimmune diabetes (incidence approximately #1%).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Research works printed but not linked: 1
- Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Paschou, S. Α., Liontos, M., Eleftherakis-Papaiakovou, E., Stefanaki, K., Markellos, C., Koutsoukos, K., Zagouri, F., Ψαλτοπούλου, Θ., & Dimopoulos, M. A. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3974547 · Cited by 1
PD-1/PD-L1 Inhibitors-Induced Hypophysitis : A real-world retrospective cohort studyPreprint
Zhu, Y.-Y., Zhang, X.-Y., Luo, S., Xu, Y., & Huang, J.-H. (2023) · Research Square · doi:10.21203/rs.3.rs-3614080/v1 · Cited by 1
Gadelha, M. R., Wildemberg, L. E., & Kasuki, L. (2022) · The Pituitary · doi:10.1016/b978-0-323-99899-4.00003-2 · Cited by 2
Database Selection and Heterogeneity—More Details, More Credibility—Reply
Barroso‐Sousa, R., Barry, W. T., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1231
Thyroid Emergencies in Critically Ill Cancer Patients
Salgado, S. A., & Thosani, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_83
Ci mancava anche un problema tiroideo…
Ruggeri, R. M., & Puxeddu, E. (2019) · L Endocrinologo · doi:10.1007/s40619-019-00645-7
Jheengut, Y., Liu, Y. Q., & Liu, L. X. (2019) · journal of nutritional oncology · doi:10.34175/jno201904002
Ramani, A., Maloney, T. G., Mills, B., Mazharuddin, S., & Mennel, R. G. (2019) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2019.1698217
Corticotherapy – an important therapeutic method in cancer treatment
Dănciulescu, M., & Lungulescu, C. V. (2019) · Oncolog-Hematolog ro · doi:10.26416/onhe.49.4.2019.2736
Chen, Z., & Hennessey, J. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-38976-5_6
Modern Multidisciplinary Care in Spine Tumors
Siontis, B. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-50722-0_5
Schilddrüsenfunktionsstörungen unter Immuncheckpoint-Inhibitor-Therapie
Theiler‐Schwetz, V., Trummer, C., Richtig, E., Richtig, G., & Pilz, S. (2020) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-020-00111-y
THYROID HOMEOSTASIS CHANGES AS THE CAUSE OF A RECURRENCE OF BENIGN FOCAL THYROID GLAND PATHOLOGY
Tkachuk, N. P. (2020) · Clinical & experimental pathology · doi:10.24061/1727-4338.xix.2.72.2020.10
Gorlin, D., Bilwani, R., Khan, S. A., Gul, M., Imam, M. H., & Chaudhry, A. (2020) · Clinical Research Open Access · doi:10.16966/2469-6714.157
免疫チェックポイント阻害薬の副作用 ～糖尿病・内分泌代謝領域～
利明, 田. (2020) · 杏林医学会雑誌 · doi:10.11434/kyorinmed.51.229
Paydary, K., Farooq, M. Z., & Mangla, A. (2020) · Endocrines · doi:10.3390/endocrines1020008
Optimizing Care for Patients With Adverse Events From Immunotherapeutics
Sheehan, K., Price, C. C., & Hafez, N. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000492
[Global research hotspots on oncology-bibliometric analysis based on the ESI hot papers].
Han, X., Li, X., Gong, X., Li, B., Bai, B., Zhang, L., Pu, J. Y., Li, Y., & Zhang, M. (2020) · PubMed · doi:10.7507/1001-5515.202009083
Non-Rheumatic Immune-Related Adverse Events
Balaji, A., Shankar, B., & Naidoo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_10
48-Year-Old Woman With Dyspnea and Chest Pain
Hwang, S. R., & Sawatsky, A. P. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.045
Neurological Toxicities of Immunotherapy
Pandey, M. R., & Ernstoff, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00020-3
Endokrynologiczne powikłania nowych terapii przeciwnowotworowych
Miner, M., Elbaum, M., Jawiarczyk-Przybyłowska, A., & Kubicka, E. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.8121
I. Hyponatremia Associated with Endocrine Diseases
Iwama, S., & Arima, H. (2020) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.109.705
Coraggio, L., & Buzzetti, R. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00882-9
Ipofisite da inibitori dei checkpoint immunologici
Nervo, A., D’Angelo, V., & Arvat, E. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00868-7
Hypophysitis due to Immune Checkpoint Inhibitors
Azar, S. T. (2021) · Endocrinology and Disorders · doi:10.31579/2640-1045/055
Immunotherapy for Metastatic Urothelial Carcinoma
Febles, V. A., & Balar, A. V. (2021) · Springer eBooks · doi:10.1007/978-3-030-70646-3_25
Punati, R., Ong, R. K. S., & Bornstein, S. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00014-4
Analysis of Pembrolizumab-induced Blood Glucose Level Change in Cancer Patients
Jung, H. Y., Hong, M.-S., Jung, W. J., Choi, S. O., Chae, J., & Yun, H. (2021) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2021.31.3.237
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Davies, M. J., & Russo, A. V. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_7
Overt Hyperthyroidism May Be a Good Prognostic Sign in Immune Checkpoint Inhibitor Treatment
Kim, B. W. (2021) · Clinical Thyroidology · doi:10.1089/ct.2021;33.467-469
Endocrinology aspects of other clinical or physiological situations
Brooke, A. M., Hirwa, K., Higham, C., & Lewis, A. A. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0012
Photoresponsive systems for biomolecular applications
Kaiser, C. (2021) · doi:10.21248/gups.64589
Lymphocytic Hypophysitis and other Inflammatory Conditions of the Pituitary
Molitch, M. E., & Kravarusic, J. (2022) · doi:10.1093/med/9780198870197.003.0035
Inibitori dei checkpoint immunitari e patologia tiroidea
Patti, L., Musso, L., Ferone, D., & Albertelli, M. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01038-z
Neuroimaging of systemic metastatic disease
Murray, J. V., Beegle, R. D., & Dodson, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00003-7
Neurological complications of lung cancer
Kaulen, L. D., Lu, B. Y., Goldberg, S. B., & Baehring, J. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00027-x
Thyroid Emergencies in Critically Ill Cancer Patients
Salgado, S. A., & Thosani, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-74698-2_83-1
Hisanaga, K., Uchino, H., Kakisu, N., Miyagi, M., Yoshikawa, F., Sato, G., Isobe, K., Kishi, K., Homma, S. A., & Hirose, T. (2020) · Research Square · doi:10.21203/rs.3.rs-49035/v1
4) Immune-related Adverse Events in Endocrine Organs Induced by Immune Checkpoint Inhibitors
Arima, H., Kobayashi, T., & Iwama, S. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1788
Clinical Features of Camrelizumab-Associated Diabetes Mellitus
Ye, D., Qiu, M., Wu, L., & Li, B. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001493
The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient
Wigmore, T., & Ward, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69584-8.00040-2
Lyu, Z., Zheng, S., Tian, S., Nie, Y., Huang, R., Zhao, H., Lou, L., Kai, G., Ye, H., & Liang, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4159562
Calabrich, A., Wainstein, A. J. A., de Melo, A. C., Buzaid, A. C., Katz, A., Ferreira, C. G., dos Anjos, C. H., Baldotto, C. S. D. R., Mathias, C. M. D. C., Gomes, E. E., et al. (2022) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20220305 · Cited by 1
Hayashida, A., Adachi, T., Kushimoto, M., Hashimoto, A., & Hamada, R. (2022) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.55.453
Endocrine side effects during cancer treatment. Lecture for practitioners
Глибка, А. А., Mazurina, N. V., & Troshina, E. A. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.6.201695
Was muss der Internist bei Patienten unter Biologikabehandlung beachten?
Zander, T., & Hallek, M. J. (2022) · rheuma plus · doi:10.1007/s12688-022-00536-0
Anti-neoplastic Immunomodulatory Treatments and the Pituitary
Rengarajan, M., & Faje, A. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_25
Kotwal, A. (2022) · Clinical Thyroidology · doi:10.1089/ct.2022;34.52-55
Childhood Neoplasms and Impact on Hormones
Hoyos-Martínez, A., & Horne, V. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_3
An update on the development of advanced drug delivery systems for the treatment of hyperthyroidism
Bairagi, U., & Mishra, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00003-7
Zhou, J., Zhang, Z., & Wu, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2222674/v1
AlHarbi, A., Alshamrani, M. A., Khan, M. A., Alnatsheh, A. H., & Aseeri, M. A. (2022) · Medical Sciences · doi:10.3390/medsci10040065
(2022) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477251-3
Omar, N. E., Afifi, H. M., Sahal, A., Mekkawi, R., & Elewa, H. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107833
Zhuge, L. (2022) · International Conference on Medical and Health Informatics (ICMHI) · doi:10.1145/3545729.3545766
Immunotherapy and Endocrine Oncology
Contreras, M., Sánchez, J. C., & Iglesias, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_242-1
A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors
Sahu, K. K., Sayegh, N., & Li, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_346-1
Endocrine Toxicities Related to Immunotherapy
Quinn, M. A., Carroll, P., & Joshi, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_348-1
The Role of Immunotherapy in Renal Cell Carcinoma
Doppalapudi, S. K., Kaldany, A., Lichtbroun, B., & Singer, E. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_232-1
Zhou, C., & Luo, P. (2022) · PanCancer · doi:10.58510/xdqx2766
Лактионов, К. К., Саранцева, К. А., Yudin, D. I., Beloyartseva, M., & Сергеевич, Ю. Г. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-4s-108-113
Development of three endocrinopathies under nivolumab therapy
Глибка, А. А., Mazurina, N. V., Gridnev, D., Саранцева, К. А., & Troshina, E. A. (2023) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2022-50-056
Diabetes inmunomediada asociada a pembrolizumab
Cubas, J. B., González, J. J. S., & Llauradó, M. M. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.02.013
Wei, Y., Hong, Y., Zhou, X., Wang, H., Zhao, R., & Ma, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2749138/v1
Giannakopoulos, A., Efthymiadou, A., & Chrysis, D. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0080
Part II : Interactive case: Drug‐induced endocrine disorders
Donihi, A. C. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1813
Immunotherapy induced hypothyroidism with hyperlipidemia: a case report and literature review
Yang, Y., & He, L. (2022) · Oncology and Translational Medicine · doi:10.1007/s10330-022-0568-8
Wang, Y., Wang, X., Cheng, L., & Zhang, G. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.09
Immune-mediated diabetes associated with pembrolizumab
Cubas, J. B., González, J. J. S., & Llauradó, M. L. M. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.02.010
Endocrinopathies Associated with Immune Checkpoint Inhibitors
Druce, I. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1210
Systemic Oncosphere: Host Endocrine System
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_22
ПОБІЧНА ДІЯ ТЕРАПІЇ ІНГІБІТОРАМИ ИМУННИХ КОНТРОЛЬНИХ ТОЧОК НА ЩИТОПОДІБНУ ЗАЛОЗУ
Starikov, V. I. (2023) · Art of Medicine · doi:10.21802/artm.2023.2.26.238
Liu, J., Qin, B., Zhang, X., Cai, L., Bai, N., Tang, Z., Chen, M., & Wang, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3119506/v1
Karra, P., Hardikar, S. S., Winn, M., Anderson, G. L., Haaland, B. A., Krick, B., Thomson, C. A., Shadyab, A. H., Luo, J., Saquib, N., et al. (2023) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-0278
A review on mesenchymal stem cell-based therapies for autoimmune disorders
Sinha, Y., Nair, G. J., Srivastava, A. K., Kumar, N. S., & Hiremath, L. (2023) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2023.15.2.0363
Endocrine side effects of immunotherapeutic drugs
Orlyk, O. S., & Garnytska, A. V. (2023) · Infusion & Chemotherapy · doi:10.32902/2663-0338-2023-3-43-48
Nikolaos, N., Christantoniou, G., Kyrka, K., Pezirkianidou, P., Bikos, V., Papadaki, K., & Tsiouda, T. (2023) · Journal of Pulmonology and Respiratory Research · doi:10.29328/journal.jprr.1001047
Früheres und schwereres Auftreten bei Diabetes-spezifischen Autoantikörpern
Müssig, K. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4565-7
Identification and Management of Immunotherapy‐Related Adverse Events in Oncology
Gümüşay, Ö., Huppert, L. A., Idossa, D. W., & Rugo, H. S. (2023) · doi:10.1002/9781119823766.ch50
Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist
Taritsa, I. C., & Choi, J. N. (2023) · Current Dermatology Reports · doi:10.1007/s13671-023-00415-7
Isaacs, J. M., Shariff, A. I., & Crawford, J. (2023) · Springer eBooks · doi:10.1007/978-3-030-93702-7_12-1
Cancer immunotherapy-associated endocrine complications and treatment strategies
Sen, K., Adhikari, M., Biswas, C., Maity, S., Chatterjee, A., & Pramanick, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00010-8
Immuntherapie mit Checkpointinhibitoren und schilddrüsentypische Komplikationen
Kreppel, B. (2024) · Angewandte Nuklearmedizin · doi:10.1055/a-2173-8595
Mhatre, M., Shinde, S., Kaur, S., Vasdev, N., Tekade, M., Pawar, B. M., Sayyed, A. A., & Tekade, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15842-1.00028-4
Wu, G., Qu, J., Zheng, J., Wu, B., Wang, T., Gan, Y., Jiang, N., Li, Y., Zhou, J., & Zhou, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4176843/v1
Isaacs, J. M., Shariff, A. I., Crawford, J., Khouri, M. G., Kheterpal, M., Sammons, S. L., Ferreira, M., Wall, A., Onken, J. E., King, L., et al. (2024) · Springer eBooks · doi:10.1007/978-3-030-93702-7_12-2
A Case Report and Literature Review of Hypothyroidism Caused by Pembrolizumab
贾, 慧. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451597
Immunotherapy-Related Hypothyroidism: Mechanisms and Management
Demir, S. Ç., & Yazıcı, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005012
Double hit — bispecific antibodies in cancer therapy
Bogdanowicz, A., Wojas‐Krawczyk, K., Krzyżanowska, N., & Krawczyk, P. A. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.98901
Nivolumab-Induced Diabetic Ketoacidosis: A Case Report
Giese, D., Elkhedr, A. E., Jnaneswaran, G., & Ernste, K. M. (2024) · Cureus · doi:10.7759/cureus.64319
Advancements in Cancer Immunotherapy: Exploring Treatment OptionsPreprint
Ahuja, S., Aden, D., Zaheer, S., Sureka, N., & Zaheer, S. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4893598
Dalmazi, G. D., Ippolito, S., Caturegli, P., & Lupi, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00072-2
Hanea, T.-E., & Goada, D. (2024) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2024.01.08
Gao, M., Wang, N., Wang, J., Ma, L., & Yang, Y.-C. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i28.6230
Endocrine toxicity of cancer immunotherapy
Das, N., Tarenia, S. S., & Kalra, S. (2024) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_19_2024
Nephrological and Rheumatic Complications of Checkpoint Inhibitors
Fenoglio, R., Roccatello, D., Barreca, A., Simone, E. D., & Sciascia, S. (2024) · Rare diseases of the immune system · doi:10.1007/978-3-031-60855-1_13
Wang, Z.-Y., Li, Y.-W., Zhang, Y.-S., & Li, Z. (2023) · New discovery. · doi:10.61958/ndyf7078
Izumi, K., Iyoda, T., Yokota, A., Kanno, M., Hoshi, M., Tokuda, E., Sasaki, E., Kanazawa, K., Kuroda, J., & Saji, S. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08928-y
Metadata
- Authors
- Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Tolaney, Sara M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 173
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC5838579
- OpenAlex
- W2760410509
- Cited by
- 1,115
- References
- 67
- Citations by year
- 2026: 113 · 2025: 134 · 2024: 116 · 2023: 138 · 2022: 173 · 2021: 150 · 2020: 150 · 2019: 93 · 2018: 46
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- JAMA Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- endocrine adverse events, immune checkpoint inhibitors, hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, insulin-deficient diabetes, PD-1 inhibitors, CTLA-4 inhibitors, PD-L1 inhibitors, combination immunotherapy, ipilimumab, nivolumab, pembrolizumab, atezolizumab, advanced solid tumors, adverse event incidence, randomized controlled trials
- MeSH terms
- Antineoplastic Agents, Immunological, Antibodies, Monoclonal, Endocrine System Diseases, Endocrine Glands, Humans, Immunotherapy, Neoplasms, Incidence, Randomized Controlled Trials as Topic, Protein Kinase Inhibitors, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
